Ligand Pharmaceuticals LGND Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's change in AP?
- Ligand Pharmaceuticals (LGND) reported change in AP of $2.71M in Q1 2026.
- How has Ligand Pharmaceuticals's change in AP changed year-over-year?
- Ligand Pharmaceuticals's change in AP increased by 226.3% year-over-year, from -$2.15M to $2.71M.
- What is the long-term trend for Ligand Pharmaceuticals's change in AP?
- Over 2 years (2021 to 2025), Ligand Pharmaceuticals's change in AP has grown at a 44.7% compound annual growth rate (CAGR), from $2.81M to $5.88M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.